Judicial Panel Consolidated Spinal Cord Stimulator Lawsuits
The panel established separate multidistrict litigation cases for claims against Nevro and Abbott Laboratories.
Updated on Oct. 8, 2026 in Healthcare
Live Poll
Should courts consolidate individual product liability lawsuits into large multidistrict litigation cases?
The Judicial Panel on Multidistrict Litigation has ordered the consolidation of lawsuits involving alleged defective spinal cord stimulators. This legal action creates two separate multidistrict litigation cases for devices produced by Nevro LLC and Abbott Laboratories.
Why it matters
Consolidating these cases streamlines the legal process by grouping similar claims that accuse manufacturers of producing defective medical equipment. The panel move rejects claims from companies that argued the lawsuits lacked common factual questions.
The Judicial Panel on Multidistrict Litigation established two distinct multidistrict litigation groups for product defect claims against Nevro LLC and Abbott Laboratories. This consolidation proceeded despite formal manufacturer arguments that the cases lacked common factual questions.
The players
Judicial Panel on Multidistrict Litigation
This federal body consists of seven sitting circuit and district judges who are appointed by the Chief Justice to manage the consolidation of complex civil litigation.
Nevro LLC
This global medical device company focuses on developing and commercializing neuromodulation technology to treat chronic pain.
Abbott Laboratories
This multinational medical devices and health care company operates across a wide range of fields including diagnostics, medical devices, and nutrition products.
The details
The panel rejected the defense position that individual lawsuits against these manufacturers were too distinct to warrant unified proceedings. By forming these MDLs, the court will now coordinate the discovery phase for the claims involving the spinal cord stimulators.
Timeline
The Judicial Panel on Multidistrict Litigation issued the consolidation ruling on October 7, 2026.
Market Landscape
This ruling follows the pattern of the 2003 consolidated litigation against Guidant Corporation regarding cardiac defibrillators by grouping device-specific defect claims into a centralized federal venue. Such consolidations often trigger broader scrutiny of product safety standards and clinical documentation within the medical device manufacturing sector.
Plaintiffs involved in these cases may experience a more efficient litigation timeline as the federal court coordinates discovery and pretrial proceedings. For the average patient, this legal development primarily serves to define the accountability of device manufacturers regarding product reliability.
The takeaway
Centralizing litigation helps prevent redundant legal efforts and establishes a unified path for addressing product liability claims against medical device firms. Patients using such devices should consult with their healthcare providers to discuss any safety notifications or device performance concerns.
Further reading
Learn more about federal litigation trends in the Healthcare section.
Source note: This article includes information reported by Law360.
Live Poll
Should courts consolidate individual product liability lawsuits into large multidistrict litigation cases?
